Month: February 2026

How to Appeal the 850 Million Claims that are Rejected Every Year and Win 70 to 90% of the Time (Ep. 44)

How to Appeal the 850 Million Claims that are Rejected Every Year and Win 70 to 90% of the Time (Ep. 44)

Healthcare claim denials are not rare administrative errors. They are systemic.

In the United States, approximately 850 million insurance claims are denied every year, roughly 17% of all submitted claims. Yet appeal win rates can range from 70% to 90%, raising a critical question:

Why are so many claims denied in the first place?

In this episode, Ralph Weber speaks with physician and Claimable co-founder Warris Bokhari about:

  • The economics behind insurance claim denials
  • The “98% of eligible claims” narrative, and what it leaves out
  • AI-driven denial systems and automated claim edits
  • Employer liability under ERISA for denied claims
  • Transplant, oncology, and specialty drug denial cases
  • The impact of 200–600 day payment delays on hospitals
  • How patients and employers can respond effectively

They discuss how insurance denials affect patients, employers, providers, and the broader healthcare system, and why appeals succeed at such a high rate when properly constructed.

For employers sponsoring self-funded health plans, this episode is a critical reminder: you are legally responsible for the decisions made on behalf of your plan.

For patients, it offers practical insight into how to push back, and win.

Ralph Weber, The Benefit Whisperer
Share with a colleague. Email ralph@thebenefitwhisperer.com · (832) 924-3330 · fixmybenefitsnow.com · Schedule a free 15 minute consultation

Money From Sick People: How PBMs Use AWP, Spread, and Rebates to Inflate Drug Costs (Ep.43)

Money From Sick People: How PBMs Use AWP, Spread, and Rebates to Inflate Drug Costs (Ep.43)

PBMs promise big “discounts,” but what if those discounts are calculated off inflated prices? In this episode of The Benefit Whisperer, Ralph Weber interviews Antonio Ciaccia (46brooklyn Research / Three Axis Advisors) to decode the drug pricing alphabet soup, AWP, MAC, NADAC, rebates, and GPOs, and explain how incentives inside the pharmacy supply chain can drive costs up while still claiming “savings.”

Antonio shares why AWP remains the bedrock of legacy PBM contracting, how generic pricing can become a “Wild West,” and why rebates often amount to “money from sick people,” especially for members in high-deductible plans. Practical, plain-English steps for employers: understand compensation, get your full contract, and demand itemized claims data.

00:00 Unveiling the Pharmacy Benefits World

01:42 Antonio’s Journey into Drug Pricing

04:23 Understanding AWP and Its Implications

09:40 The Illusion of Discounts in Drug Pricing

13:06 The Role of PBMs in Drug Pricing

17:02 Challenges in Changing PBM Contracts

20:42 The Financial Incentives of PBMs

22:54 PBM Dysfunction in the Broader Healthcare Context

25:34 The Role of PBMs in Drug Pricing

27:57 Empowering Employers in Drug Cost Management

32:46 Decoding Drug Pricing Acronyms

36:30 The Impact of GPOs and Rebates on Drug Costs

41:44 Understanding the Burden on Patients and Employers

Ralph Weber, The Benefit Whisperer
Share with a colleague. Email ralph@thebenefitwhisperer.com · (832) 924-3330 · fixmybenefitsnow.com · Schedule a free 15 minute consultation